Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

FDA, EMA to review Novartis' siponimod for secondary progressive MS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/09/2018 | 10:27am CEST

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA and MAA have accepted applications for siponimod (BAF312) to treat secondary progressive multiple sclerosis (SPMS). The PDUFA date for the NDA is in March 2019; Novartis expects a decision from EMA in late 2019.

The pharma used a Priority Review voucher to speed siponimod's review. Novartis spokesperson Eric Althoff said the company used the voucher it purchased from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in 2017; Novartis paid $130 million for the voucher (see "Novartis Buying Ultragenyx's Priority Review Voucher").

The applications are supported by data from the Phase III EXPAND trial which showed that siponimod reduced the risk of six-month confirmed disability progression by 26% compared with placebo (20% vs. 26%, HR=0.74, 95% CI: 0.6, 0.92, p=0.0058) in SPMS patients (see "Novartis Planning Submissions for Secondary Progressive MS Candidate").

Siponimod is a second-generation sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist. It was designed to avoid some of the cardiovascular side effects seen with Novartis' MS drug Gilenya fingolimod, a first-generation S1P receptor agonist (see "Devil Is in the Dosing").

Celgene Corp. (NASDAQ:CELG) is developing ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator. In February, FDA issued a refusal to file letter for ozanimod in relapsing MS (see "Rocky Road").

In July, Celgene said it expects to submit in 1Q19 regulatory applications in the U.S. and EU for ozanimod.

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
CELGENE CORPORATION -0.65% 82.41 Delayed Quote.-21.59%
NOVARTIS 1.35% 87.04 Delayed Quote.0.07%
ULTRAGENYX PHARMACEUTICAL INC -1.34% 63.28 Delayed Quote.33.23%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
10/19ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Brazil for the Tre..
AQ
10/18Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazi..
GL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/19ULTRAGENYX PHARMACEUTICAL : appoints Dr. Wladimir Hogenhuis as COO
AQ
09/17ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers, Fina..
AQ
More news
News from SeekingAlpha
09/27Ultragenyx's DTX301 shows positive effect in OTC study 
09/17Ultragenyx appoints Dr. Wladimir Hogenhuis as COO 
09/10Premarket analyst action - healthcare 
09/05Gene therapy players under pressure 
08/29YOUR DAILY PHARMA SCOOP : ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozemp.. 
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,0x
EV / Sales 2019 27,4x
Capitalization 3 176 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 219
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222